The global renal insufficiency treatment market garnered a market value of USD 12 Billion in 2022 and is expected to accumulate a market value of USD 35.28 Billion by registering a CAGR of 10.3% in the forecast period 2023 to 2033. Growth of the renal insufficiency treatment market can be attributed to increasing number of patients with chronic kidney disease, the rising adoption of advanced dialysis techniques, and the development of new and more effective medications for the treatment of renal insufficiency. The market for renal insufficiency treatment registered a CAGR of 5.8% in the historical period 2018 to 2022
Renal insufficiency, also known as chronic kidney disease, is a condition in which the kidneys are not functioning properly. Treatment for renal insufficiency typically focuses on managing the underlying cause of the disease and preventing further damage to the kidneys.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 13.24 Billion |
| Anticipated Forecast Value (2033) | USD 35.28 Billion |
| Projected Growth Rate (2023 to 2033) | 10.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Renal insufficiency treatment reflected a value of 5.8% during the historical period, 2018 to 2022.
Increasing prevalence of chronic kidney disease, the rising adoption of home-based dialysis treatments, and the introduction of new and more effective drugs for the treatment of renal insufficiency contributed to the growth of the market in the historical period. Additionally, the COVID-19 pandemic in 2020 and 2021 had a significant impact on the market, with disruptions to supply chains and a decrease in patient visits to healthcare facilities.
Overall, the renal insufficiency treatment market is expected to be driven by a combination of increasing demand for treatment and ongoing innovation in the development of new therapies and treatment options.
Thus, the market for Renal insufficiency treatment is expected to register a CAGR of 10.3% in the forecast period 2023 to 2033.
Increasing prevalence of chronic kidney disease favoring the growth of market
The increasing prevalence of chronic kidney disease is one of the primary drivers of the renal insufficiency treatment market. According to the National Kidney Foundation, about 37 Billion people in the United States alone have chronic kidney disease. This high prevalence is driving demand for treatments and therapies to manage the condition.
Advancements in dialysis technology, such as the development of home-based and portable dialysis machines, are expanding access to treatment for renal insufficiency patients. These advancements are making it easier for patients to receive dialysis in a variety of settings, including their homes, which is improving their quality of life.
The development of new medications for the treatment of renal insufficiency is another driver of the market. Many pharmaceutical companies are investing in research and development to create new therapies that can slow the progression of chronic kidney disease and reduce the risk of complications.
The aging population is also a driver of the renal insufficiency treatment market, as the risk of chronic kidney disease increases with age. As the population continues to age, the demand for treatments and therapies to manage renal insufficiency is expected to increase.
Increasing awareness and education about chronic kidney disease and the importance of early detection and management is also driving the market. As more people become aware of the risks associated with chronic kidney disease, they are more likely to seek treatment and take steps to manage the condition.
Availability of treatments shaping landscape for renal insufficiency treatment market
Medications: Medications can be used to control high blood pressure, reduce proteinuria (excess protein in the urine), manage anemia, and lower cholesterol levels. Some medications can also slow the progression of chronic kidney disease.
Dietary changes: Dietary changes may include reducing the intake of sodium, potassium, and phosphorus, as well as increasing the intake of protein and calories. These changes can help manage symptoms and slow the progression of the disease.
Dialysis: Dialysis is a procedure that filters waste and excess fluids from the blood when the kidneys are not functioning properly. There are two main types of dialysis: hemodialysis and peritoneal dialysis.
Kidney transplant: A kidney transplant involves receiving a healthy kidney from a donor, which can restore normal kidney function. This is usually considered when other treatments are no longer effective.
Management of underlying conditions: Treating underlying conditions that contribute to chronic kidney disease, such as diabetes or high blood pressure, can also help manage the disease and prevent further damage to the kidneys.
Principal Consultant
Limited healthcare resources and expensive nature of treatment derailing growth of renal insufficiency market
The cost of renal insufficiency treatment is high, and it can be a significant burden for patients and healthcare systems. Dialysis and kidney transplant can be expensive, and medications used to manage chronic kidney disease can also be costly.
In some regions, healthcare resources are limited, and access to treatment for renal insufficiency may be difficult. This can be due to a lack of medical facilities, trained healthcare professionals, or funding. Adherence to treatment can be a challenge for patients with chronic kidney disease. Treatment often involves significant lifestyle changes, such as dietary modifications and regular medical appointments, which can be difficult for patients to manage over the long term.
Underdiagnosis and late detection of chronic kidney disease can lead to delayed treatment and poorer outcomes. Lack of awareness and routine screening for chronic kidney disease may contribute to underdiagnosis.
Treatment for renal insufficiency can sometimes have significant side effects, which can be a challenge for patients to manage. For example, dialysis can cause fatigue, nausea, and muscle cramps, while some medications can cause gastrointestinal upset or skin rashes.
Advancements in treatment options propelling the treatment options for renal insufficiency
The North America renal insufficiency treatment market is one of the largest in the world, with the United States and Canada being the major contributors. The market is driven by factors such as the high prevalence of chronic kidney disease (CKD), advancements in dialysis technology, and the increasing awareness about kidney diseases and their management.
The United States is the largest market for renal insufficiency treatment in North America, with a high prevalence of CKD and a large aging population. According to the National Kidney Foundation, more than 37 Billion Americans have CKD, and the disease is the ninth leading cause of death in the country. The availability of advanced dialysis technology, such as home-based and portable dialysis machines, is also contributing to the growth of the market.
Canada is another significant market for renal insufficiency treatment in North America. The country has a universal healthcare system that provides coverage for dialysis and kidney transplant, which has led to high rates of treatment for CKD patients. The Canadian Society of Nephrology reports that there are more than 23,000 patients on dialysis in Canada, and more than 3,000 kidney transplants have been performed in the country since 2008.
Overall, the North America renal insufficiency treatment market is expected to continue to grow in the coming years, driven by factors such as the increasing prevalence of CKD, advancements in treatment options, and growing awareness about kidney disease management. Thus, North America is expected to possess 48% market share for renal insufficiency in 2023.
Aging population contributing to market growth for renal insufficiency in Europe
The Europe renal insufficiency treatment market is a significant contributor to the global renal insufficiency treatment market. The market is driven by factors such as the increasing prevalence of chronic kidney disease (CKD), the availability of advanced treatment options, and the growing awareness about kidney disease management.
The United Kingdom, Germany, and France are some of the major markets for renal insufficiency treatment in Europe. The high prevalence of CKD and the availability of advanced treatment options, such as home-based and portable dialysis machines, are contributing to the growth of the market in these countries.
The United Kingdom has a high prevalence of CKD, with more than three Billion people in the country suffering from the disease, according to the National Kidney Federation. The country also has a well-established healthcare system that provides coverage for dialysis and kidney transplant, which has led to high rates of treatment for CKD patients.
Germany is another significant market for renal insufficiency treatment in Europe. The country has a large aging population, which is contributing to the growth of the market. The availability of advanced dialysis technology, such as high-flux dialysis and hemodiafiltration, is also contributing to the growth of the market in Germany.
France is also a major market for renal insufficiency treatment in Europe. The country has a high prevalence of CKD, with more than three Billion people in the country suffering from the disease, according to the French Society of Nephrology. The country also has a well-established healthcare system that provides coverage for dialysis and kidney transplant. Thus, Europe is expected to possess 41% market share for renal insufficiency in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Advanced dialysis technology making dialysis process easier for patients in renal insufficiency treatment
Dialysis centres can be a good option for renal insufficiency treatment, particularly for patients with end-stage renal disease (ESRD) who require regular dialysis treatment. Dialysis centres are specialized facilities designed specifically to provide dialysis treatment to patients with kidney failure.
Dialysis treatment involves removing waste and excess fluid from the blood when the kidneys are no longer able to do so on their own. This treatment can help manage the symptoms of kidney failure and improve the patient's quality of life.
Dialysis centres offer patients access to specialized medical care and support from a team of healthcare professionals, including nephrologists, nurses, and dialysis technicians. These centres are equipped with advanced dialysis technology and are staffed by trained healthcare professionals who can monitor patients closely and adjust their treatment as needed. Thus, dialysis centres are expected to possess 45% market share for renal insufficiency treatment market in 2023.
Key players in the renal insufficiency treatment are Nipro Corp., Fresenius Medical Care AG & Co. KGaA, Baxter International, Inc., Medtronic Plc, Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., Cantel Medical, Nikkiso Co., Ltd., JMS Co. Ltd., AstraZeneca
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 13.24 Billion |
| Market Value in 2033 | USD 35.28 Billion |
| Growth Rate | CAGR of 10.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment Type, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Nipro Corp.; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; Braun Melsungen AG; Asahi Kasei Medical Co., Ltd.; Cantel Medical; Nikkiso Co., Ltd.; JMS Co. Ltd.; AstraZeneca |
| Customization | Available Upon Request |
From 2018 to 2022, the Renal insufficiency treatment market grew at a CAGR of 5.8%
The global Renal insufficiency treatment market is expected to grow with a 10.3% CAGR during 2023 to 2033.
As of 2033, the Renal insufficiency treatment market is expected to reach USD 35.28 Billion
Dialysis centres are expected to hold 45% of the market share in 2023 for Renal insufficiency treatment market.
North America is expected to possess 48% market share for Renal insufficiency treatment market in 2023.
Europe Renal insufficiency treatment market size is expected to possess 41% market share in 2023.
1. Executive Summary | Renal Insufficiency Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Dialysis 5.2. Medication 5.3. Kidney Transplantation 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Dialysis Centres 6.2. Hospital & Clinics 6.3. Research & Academic Institutes 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia 7.5. East Asia 7.6. Oceania 7.7. MEA 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Nipro Corp. 17.2. Fresenius Medical Care AG & Co. KGaA 17.3. Baxter International, Inc. 17.4. Medtronic Plc 17.5. B. Braun Melsungen AG 17.6. Asahi Kasei Medical Co., Ltd. 17.7. Cantel Medical 17.8. Nikkiso Co., Ltd. 17.9. JMS Co. Ltd. 17.10. AstraZeneca 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Renal Insufficiency Treatment Market
